Prometheus Laboratories empowers healthcare professionals to diagnose, treat and help get their IBD patients into remission faster with precision-guided care. Their proprietary continuum of testing solutions aids in individualizing the entire patient care journey – from disease interception through monitoring – with the goal of patients achieving and maintaining long-term remission.
Prometheus offers a robust portfolio of tests, including IBD sgi Diagnostic® which combines serologic, genetic and inflammation markers to help differentiate IBD vs non-IBD and ulcerative colitis vs Crohn’s disease while offering risk stratification of disease phenotypes.
Role within INTERCEPT
Prometheus is providing support to INTERCEPT with the measurement of microbial antibodies (e.g. ASCA) that will help with the interception of first-degree relatives having a high risk for developing Crohn’s disease. In addition, Prometheus will provide guidance with the regulatory approval of the INTERCEPT panel of markers in the clinical laboratory framework of the United States
Main contacts
Thierry Dervieux
Chief Scientific Officer
Claudia Ibarra
Senior VP Technical Operation
Annelie Everts van der Wind
Director biobanking